Table 4.

Adverse events occurring in ≥10% of patients in the Japanese safety-evaluable subgroup

	Atezolizumab + nab-paclitaxel (n = 34)		Placebo + nab-paclitaxel (n = 30)
	Any grade in ≥10% of patients	Grade ≥ 3	Any grade in ≥10% of patients	Grade ≥ 3
Patients with ≥1 event, n (%)	34 (100)	13 (28.2)	30 (100)	12 (40.0)
Alopecia	29 (85.3)	0	26 (86.7)	0
Peripheral sensory neuropathy	20 (58.8)	0	15 (50.0)	0
Nausea	16 (47.1)	0	12 (40.0)	1 (3.3)
Neutrophil count decreased	15 (44.1)	6 (17.6)	10 (33.3)	5 (16.7)
Nasopharyngitis	11 (32.4)	0	3 (10.0)	0
Rash	10 (29.4)	0	6 (20.0)	0
White blood cell count decreased	10 (29.4)	4 (11.8)	3 (10.0)	2 (6.7)
Stomatitis	9 (26.5)	0	3 (10.0)	0
Constipation	8 (23.5)	0	10 (33.3)	0
Dysgeusia	8 (23.5)	0	9 (30.0)	0
Pyrexia	8 (23.5)	0	6 (20.0)	0
Fatigue	8 (23.5)	0	6 (20.0)	0
Peripheral oedema	8 (23.5)	0	6 (20.0)	0
Nail discoloration	7 (20.6)	0	9 (30.0)	0
Decreased appetite	7 (20.6)	0	8 (26.7)	1 (3.3)
Vomiting	7 (20.6)	1 (2.9)	3 (10.0)	0
Paronychia	7 (20.6)	0	0	0
Myalgia	6 (17.6)	0	7 (23.3)	1 (3.3)
Anaemia	6 (17.6)	0	7 (23.3)	0
Dry skin	6 (17.6)	0	6 (20.0)	0
Diarrhoea	6 (17.6)	0	5 (16.7)	0
Headache	6 (17.6)	0	4 (13.3)	0
Pruritis	6 (17.6)	0	2 (6.7)	0
Malaise	5 (14.7)	0	10 (33.3)	0
Alanine aminotransferase increased	5 (14.7)	0	8 (26.7)	1 (3.3)
Aspartate aminotransferase increased	4 (11.8)	0	5 (16.7)	1 (3.3)
Arthralgia	4 (11.8)	0	4 (13.3)	0
Urinary tract infection	4 (11.8)	0	1 (3.3)	0
Insomnia	4 (11.8)	0	1 (3.3)	0
Neutropenia	4 (11.8)	3 (8.8)	0	0
Hypothyroidism	4 (11.8)	0	0	0
Oedema	3 (8.8)	0	3 (10.0)	0
Peripheral neuropathy	2 (5.9)	0	5 (16.7)	0
Cough	2 (5.9)	0	4 (13.3)	0
Pharyngitis	2 (5.9)	0	3 (10.0)	0